Lhasa Limited shared knowledge shared progress
Publications
  • Publisher:
    Elsevier
  • Publication Date:
    Aug 2017
  • Reference:
    Regulatory Toxicology and Pharmacology, Volume 90, November 2017, Pages 22-28
  • DOI:
  • PMID:
  • Publication Type:
    Paper
  • Related Products:
  • Scientific Area:
  • Endpoint:
  • Industry Type:
  • Related event:

A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies

Barber CG; Antonucci V; Baumann J-C; Brown R; Covey-Crump E; Elder DP; Jordine G; Kallemeyn JM; Molzahn R; Ott MA; Elliott E; Fennell JW; Gallou F; Ide ND; Teasdale A; Urquhart MW; Lauwers D; Looker AR; Lovelle LE; McLaughlin M; Varie DL; Welch D; Schils D; Schulte Oestrich R; Stevenson N; Talavera P;

The ICH M7 Option 4 control of (potentially) mutagenic impurities is based on the use of scientific principles in lieu of routine analytical testing. This approach can reduce the burden of analytical testing without compromising patient safety, provided a scientifically rigorous approach is taken which is backed up by sufficient theoretical and/or analytical data. This paper introduces a consortium-led initiative and offers a proposal on the supporting evidence that could be presented in regulatory submissions.

Download

© 2018 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.

IP: 54.227.31.145 | Group: ###groupid###